Nykredit A/S’s Vertex Pharmaceuticals VRTX Stock Holding History

Nykredit A/S’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123M	Buy	+248,068	New	+$110M	0.39%	60

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Nykredit A/S's VRTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 248,068 shares worth $123M. The stake represents 0.39% of the portfolio and ranks #60 among its holdings.

1,403 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Nykredit A/S held 248,068 shares of Vertex Pharmaceuticals worth $123M as of Q2 2026.
Vertex Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Vertex Pharmaceuticals made up 0.39% of Nykredit A/S's portfolio in Q2 2026, its #60 holding.
1,403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.